eFFECTOR Therapeutics Inc (EFTR) Quote

What is interesting

Interesting

EFTR: effective Jan. 12,2024 a one for 25 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

https://stockcharts.com/h-sc/ui?s=eftr&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2

geez

POS not done dumping eh

Low Volume movement . .

R.I.P OR RIP LIKE A SAW BLADE

R.I.P OR RIP LIKE A SAW BLADE

rip

dip

dip

strong

strong

R.I.P OR RIP LIKE A SAW BLADE

rip

$EFTR
$EFTR Banger of a chart here..with no signs of slowing down..
TommyBoyTrader Telegram Room has eyes on this one..stop by and check us all out..all are welcome..https://t.co/hgN1IiEdJp pic.twitter.com/Y8yV7XTNxk— Tommy Boy Trader (@QuabbinR) June 5, 2023

nice

runs again

monster volume

monster volume

EFTR: They were the GREATEST!! (Lots of junk stuff, too; but what comedy team even comes close??? NONE!!!)

I am a 3 stooges historian. Curly died at 48 years old. Moe wrote in his book that Curly was an all-natural funny guy! Although Shemp was the original stooge, he left because he didn't get along with Ted Healy who at the beginning was the Stooges' leader. A few years later Moe and Larry broke off with Healy and became the 3 stooges with the addition of Curly to replace Shemp as Shemp started his own series of short films

EFTR: YEP!! (But they were much FUNNIER, when "Curly" joined them; JOE PISCAPO used to do a great impersonation of him years ago, on SNL; see Joe below, but give the link a little time to RUN to Joe.)

It's classic! All those things from almost 100 years ago. Hard for me to fathom how fast the time has gone by!

EFTR: And indeed, I DID "die laughing"!!! (Just came back to LIFE, Boss!!! See me, below, right now!!!)


That's ME, on the table!!! (Hey, S-L, go EASY on me with your funny stuff, Boss!!)

PS: And, did you know that BRUCE LEE learned ALL of his legendary KUNG FU moves from that one Stooges' flick alone!!!

One of my all-time favorites. Prepare to die laughing.

EFTR: Hey, get this, Boss!!! iHub's own (Ms.) "GAIL" is related to Mr. Nuck-Nuck-Nuck-Nuck!!! (Me & GAIL used to kick-it-around for MONTHS here on iHub. But, after I posted some TRASH about TRUMP --- whom she "LOVES" --- Ms. GAIL dumped me big-time! Politically & socially, she's Far-Right, while I'm Medium-Left. GAIL's a retired Police Officer, in Virginia. You, yourself, have SURELY encountered her on iHub on countless occasions through the years.)

PS: One of the singularly-funniest bits in US HISTORY, is the 3-Stooges' "AMATEUR DENTIST" routine, way back in the circa late 1940's. (I found it on the Net several years ago, but could NOT locate it again recently though; especially since they made MANY such DENTIST bits through their years. See one, below, but it is HARDLY their funniest.)

He was drinking buddie to WC Fields. That alone says that Shemp Howard was a genus. :)

EFTR: Yep; THAT member of the Holy Trinity of Comedy was conspicuously NOT a pretty man, by any means, Sir!!!

yuk yuk https://travsd.files.wordpress.com/2013/03/url9.jpg

EFTR: I had anticipated that ya just might get a little CHUCKLE behind THAT post. (Just about the FUNNIEST GIF on the Planet here right now.)

EFTR: CUTE!!! (Heck, I gots THAT label on the front door of my house here in San Diego, for God's sake!!)

LMAO!

EFTR: Hey, Colonel S-L!! Check-out (below) an old selfie film-clip of ME --- when I was at a Frat Party at UCONN decades ago --- and a fellow Pledge had spiked our BEERS with POT!!!! Boy, I'll-tell-ya, I just HATE when THAT happens!!!

https://stock.adobe.com/images/thc-warning-label-sticker-canadian-cannabis-warning-symbol-icon/522349801?asset_id=522349801

https://stock.adobe.com/images/thc-warning-label-sticker-canadian-cannabis-warning-symbol-icon/522349801?asset_id=522349801

EFTR: WHAT???!!! Pot-in-the-PUNCH????!!!!!

Reminds me of when my friend put THC in the Christmas Party punch and didn't tell anybody 50 years ago

Reminds me of when my friend put THC in the Christmas Party punch and didn't tell anybody 50 years ago

solid

EFRT: O.K., see my live reaction to your msg. (just now) below!!

On May 25, 2023, eFFECTOR Therapeutics, Inc. (the “Company”) announced positive interim data updates from a Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib (“ZFA triplet”) in patients with ER+ metastatic breast cancer (“mBC”). These data, as well as initial data from further dose escalation, will be presented as part of a poster presentation at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.

New interim data were presented on the fully enrolled expansion cohort of patients (n=20) who received the ZFA triplet with zotatifin dosed at 0.07 mg/kg on Days 1 and 8 of 21-day cycles. Patients were heavily pre-treated, having received a median of four prior lines of therapy for metastatic disease. Five out of 19 (26%) RECIST-evaluable patients achieved a partial response (“PR”), including four confirmed and one unconfirmed. All five patients who achieved a PR had previously progressed on prior CDK4/6 and fulvestrant treatments, and all 5 had received one or more prior lines of chemotherapy. The disease control rate (“DCR”), reflecting patients with at least one on-treatment scan showing PR or stable disease (“SD”), was 14 of 19 (74%). PRs were seen in patients with and without mutations in the ESR1 and PIK3CA genes. As of the data cutoff date, 4 patients remained on therapy and progression free survival (“PFS”) as well as clinical benefit rate (“CBR”) data are not yet mature. The ZFA triplet was generally well tolerated, with 3 patients discontinuing due to adverse events (“AEs”) of any cause, and the large majority of AEs being Grade 1 or 2. The most frequent Grade 3 AEs were diarrhea in 3 of 20 (15%) patients, similar to the 13% frequency reported in the registrational Monarch 2 trial for abemaciclib and fulvestrant, and dyspnea in 2 of 20 (10%) patients.

New data were also reported for patients in resumed dose escalation cohorts utilizing zotatifin combined with fulvestrant (“ZF doublet”). In the one fully enrolled cohort, wherein patients received zotatifin dosed at 0.1 mg/kg every other week (“Q2W”) combined with fulvestrant, 1 of 3 (33%) patients achieved a PR on the first on-treatment scan, which was confirmed on the second on-treatment scan that occurred after the data cutoff, and remained on study. This patient had received four lines of prior therapy for metastatic disease, with progressive disease (“PD”) being the best overall response (“BOR”) to all four prior lines. Dose escalation is continuing at 0.14 mg/kg Q2W and 0.07 mg/kg once weekly (“QW”). Zotatifin has been generally well tolerated in dose escalation cohorts, with no dose limiting toxicities or serious adverse events observed.

Data for the ZF doublet with zotatifin at 0.07 mg/kg dosed on Days 1 and 8 of 21-day cycles, originally reported on January 5, 2023, were also updated. The patient with a confirmed PR showed a duration of response (“DOR”) of approximately 13 months. The patient with prolonged SD remained on study at 12 months. The Company expects to report topline data from completed dose escalation cohorts evaluating ZF in the second half of 2023.

Data on changes in circulating tumor DNA (“ctDNA”) were also updated from January 5, 2023, when the Company reported a dose-dependent decrease in ctDNA in patients receiving zotatifin-based regimens. In the new data set, 9 patients who received the ZFA triplet at 0.07 mg/kg zotatifin had both pre- and on-treatment samples available for ctDNA analysis. Four additional patients came off study prior to the protocol-specified time to collect on-treatment ctDNA (Day 43). Eight patients had decreases in ctDNA of greater than 50%, representing 89% of the patients with on-treatment samples available for analysis, and 62% of patients who either had available on-treatment samples or who had discontinued prior to collection of on-treatment samples. The specific alleles observed to be decreased or eliminated in on-treatment ctDNA, including mutations in ESR1 and PIK3CA genes, reflect common mechanisms of resistance to endocrine therapy in ER+ BC and are consistent with zotatifin’s mechanism of action maintaining sensitivity after resistance to endocrine therapy has emerged. The patient who achieved a confirmed PR in the ZF dose escalation group also eliminated detectable ctDNA at Day 29, including mutant alleles of ESR1 and ERBB2 genes, after having received only two doses of zotatifin.

All data was presented as of a data cut-off date of May 3, 2023.

Fake wall needs to get obliterated

Does this have a collaboration with Pfizer and when is their next study announcement due? Is it July or September for Zotatifin?

JMP Securities Sticks to Their Buy Rating for eFFECTOR Therapeutics (EFTR)
August 11 2022 - 12:15AM
TipRanks

Share On Facebook
In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on eFFECTOR Therapeutics (EFTR - Research Report), with a price target of $5.00. The company's shares closed yesterday at $0.73.According to TipRanks, Benjamin is an analyst with an average return of -6.0% and a 37.63% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, CTI BioPharma, and Incyte.eFFECTOR Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.00, a 3,303.68% upside from current levels. In a report released yesterday, Credit Suisse also maintained a Buy rating on the stock with a $10.00 price target.
https://www.tipranks.com/news/blurbs/jmp-securities-sticks-to-their-buy-rating-for-effector-therapeutics-eftr?utm_source=advfn.com&utm_medium=referral

THANKS, C-O-24!! (Always appreciated!!)

Ratcheting up along with R*SLS.

EFTR: I copy that, CPT.!! Thanks!! (& they got WARRANTS, too.)

Therapeutics is a Strong Buy with an average price target of $26.00